- New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide
- Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)
- Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME
- Company core asset, givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, continues to advance under previously announced investment plans
ROCKVILLE, Md., Oct. 29, 2025 -- NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company's Extraordinary General Meeting held on October 24, 2025, and by the Company's Board of Directors. The Company's American Depositary Shares (ADSs) will trade on Nasdaq under the new name and a new ticker symbol, "NBP", effective at the opening of trading on October 30, 2025, replacing its current symbol "IMAB" (Nasdaq: IMAB).
The new corporate brand, including a new website (www.novabridge.com), marks an important step in the Company's strategic transformation to a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide.
In connection with the name change and ticker symbol change, no action is required from current shareholders and the Company's CUSIP number will remain the same. Historical trading data of the Company's ADSs prior to October 30, 2025 may not yet be available on certain third-party websites and apps when searching for "NovaBridge Biosciences" and/or "NBP", in which case such data may temporarily be found under "I-MAB" and/or "IMAB".
Overview of the NovaBridge Biosciences
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
